{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:08:47Z","timestamp":1789520927566,"version":"build-2803163510"},"reference-count":202,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000964","name":"Arthritis National Research Foundation","doi-asserted-by":"publisher","award":["CRG\/2023\/001951"],"award-info":[{"award-number":["CRG\/2023\/001951"]}],"id":[{"id":"10.13039\/100000964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017531","name":"Gandhi Institute of Technology and Management","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbcan.2026.189696","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T14:28:35Z","timestamp":1788100115000},"page":"189696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic therapy-induced resistance and toxicity in breast cancer: Sensitization and mitigation strategies"],"prefix":"10.1016","volume":"1881","author":[{"given":"Anuveda Sree","family":"Samudrala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganji Purnachandra","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RamaRao","family":"Malla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0005","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189696_bb0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast Edinb. Scotl."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0015","first-page":"171","article-title":"Breast cancer treatment","volume":"104","author":"Trayes","year":"2021","journal-title":"Am. Fam. Physician"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0020","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-020-05730-2","article-title":"Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia","volume":"182","author":"Zhang","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"Suppl 1(Suppl 1)","key":"10.1016\/j.bbcan.2026.189696_bb0025","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.breast.2022.01.006","article-title":"Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer","volume":"62","author":"Harbeck","year":"2022","journal-title":"Breast Edinb. Scotl."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189696_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102375","article-title":"Adjuvant and neoadjuvant breast cancer treatments: a systematic review of their effects on mortality","volume":"105","author":"Kerr","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41523-024-00699-3","article-title":"Predictors of response to CDK4\/6i retrial after prior CDK4\/6i failure in ER+ metastatic breast cancer","volume":"10","author":"Mai","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073904","article-title":"Hinokitiol inhibits breast Cancer cells in vitro Stemness-progression and self-renewal with apoptosis and autophagy modulation via the CD44\/Nanog\/SOX2\/Oct4 pathway","volume":"25","author":"Chiang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189696_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155651","article-title":"In silico analysis and comprehensive review of circular-RNA regulatory roles in breast diseases; a step-toward non-coding RNA precision","volume":"263","author":"Hamdy","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0055","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.gendis.2020.11.015","article-title":"Tumor microenvironment pathways: cross regulation in breast cancer metastasis","volume":"9","author":"Malla","year":"2022","journal-title":"Genes Dis"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0060","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1186\/s12885-019-5939-z","article-title":"Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model","volume":"19","author":"Christowitz","year":"2019","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189696_bb0065","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/ndt\/gfae046","article-title":"Relative survival in patients with cancer and kidney failure","volume":"39","author":"Oliveras","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0070","first-page":"769","article-title":"Paclitaxel anti-cancer therapeutics: from discovery to clinical use","volume":"23","author":"Yu","year":"2025","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189696_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1363803","article-title":"Metabolic engineering of Streptomyces peucetius for biosynthesis of N,N-dimethylated anthracyclines","volume":"12","author":"Hulst","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189696_bb0080","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1111\/febs.15583","article-title":"New insights into the activities and toxicities of the old anticancer drug doxorubicin","volume":"288","author":"van der Zanden","year":"2021","journal-title":"FEBS J."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41416-023-02158-5","article-title":"Tamoxifen evolution","volume":"128","author":"Howell","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189696_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117894","article-title":"Advancements in platinum-based anticancer drug development: a comprehensive review of strategies, discoveries, and future perspectives","volume":"112","author":"Sahoo","year":"2024","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0095","article-title":"Platinum-containing regimens for metastatic breast cancer","volume":"6","author":"Egger","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189696_bb0100","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1158\/0008-5472.CAN-16-0150","article-title":"A retrospective: on clinical studies with 5-fluorouracil","volume":"76","author":"Jordan","year":"2016","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0105","first-page":"69","article-title":"Fluorouracil for advanced breast cancer","volume":"94","author":"Solheim","year":"1974","journal-title":"Tidsskr. Nor. Laegeforen."},{"key":"10.1016\/j.bbcan.2026.189696_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003374.pub3","article-title":"Platinum containing regimens for metastatic breast cancer","volume":"2","author":"Carrick","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0115","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/0008-5472.CAN-22-2709","article-title":"Protein phosphatase 1 subunit PPP1R14B stabilizes STMN1 to promote progression and paclitaxel resistance in triple-negative breast cancer","volume":"83","author":"Liao","year":"2023","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189696_bb0120","doi-asserted-by":"crossref","first-page":"10940","DOI":"10.7150\/thno.45207","article-title":"SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer","volume":"10","author":"Liu","year":"2020","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70203","article-title":"RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic-nuclear shuttling in human triple-negative breast cancer","volume":"15","author":"Huang","year":"2025","journal-title":"Clin. Transl. Med."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189696_bb0130","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.7150\/thno.36338","article-title":"CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1\/P50","volume":"9","author":"Chi","year":"2019","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0135","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/CAD.0000000000001048","article-title":"Nuclear Her2 contributes to paclitaxel resistance in breast cancer cells","volume":"32","author":"Luo","year":"2021","journal-title":"Anti-Cancer Drugs"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0140","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3892\/ol.2021.13168","article-title":"Paclitaxel resistance is mediated by NF-\u03baB on mesenchymal primary breast cancer cells","volume":"23","author":"Esparza-L\u00f3pez","year":"2022","journal-title":"Oncol. Lett."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189696_bb0145","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/1389557520999201214234421","article-title":"Resistance to intervention: paclitaxel in breast cancer","volume":"21","author":"Dan","year":"2021","journal-title":"Mini-Rev. Med. Chem."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-22-0423","article-title":"JAK-STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states","volume":"83","author":"Stevens","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0155","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2488127","article-title":"Discovery and biological evaluation of a novel and highly potent JAK2 inhibitor for the treatment of triple negative breast cancer","volume":"40","author":"Miao","year":"2025","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189696_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.718721","article-title":"Breast Cancer stem cell-derived ANXA6-containing exosomes sustain paclitaxel resistance and cancer aggressiveness in breast cancer","volume":"9","author":"Guo","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189696_bb0165","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.chembiol.2024.08.003","article-title":"A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Cell Chem. Biol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0170","doi-asserted-by":"crossref","first-page":"411","DOI":"10.7555\/JBR.35.20210105","article-title":"Paclitaxel-induced stress granules increase LINE-1 mRNA stability to promote drug resistance in breast cancer cells","volume":"35","author":"Shi","year":"2021","journal-title":"J. Biomed. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0175","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s41065-025-00534-0","article-title":"RBM15 enhances paclitaxel resistance in triple-negative breast cancer by targeting m(6)a methylation of TNFSF9 and inducing polarization of tumor-associated macrophages to M2 phenotype","volume":"162","author":"Fu","year":"2025","journal-title":"Hereditas"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12493","article-title":"Baohuoside I chemosensitises breast cancer to paclitaxel by suppressing extracellular vesicle\/CXCL1 signal released from apoptotic cells","volume":"13","author":"Wang","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.bbcan.2026.189696_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.784777","article-title":"Hypoxia-induced intracellular and extracellular heat shock protein gp96 increases paclitaxel-resistance and facilitates immune evasion in breast cancer","volume":"11","author":"Tian","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0190","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13058-025-02082-x","article-title":"Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer","volume":"27","author":"Skourti","year":"2025","journal-title":"Breast Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189696_bb0195","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.stemcr.2017.03.026","article-title":"Resistance to taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor-initiating population","volume":"8","author":"G\u00f3mez-Miragaya","year":"2017","journal-title":"Stem Cell Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0297260","article-title":"Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis","volume":"19","author":"Gao","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189696_bb0205","article-title":"Paclitaxel resistance modulated by the interaction between TRPS1 and AF178030.2 in triple-negative breast cancer","volume":"2022","author":"Zhao","year":"2022","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0210","first-page":"197","article-title":"Taxane resistance in breast cancer: a closed HER2 circuit?","volume":"1825","author":"de Hoon","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0215","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.ajpath.2012.02.024","article-title":"Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298","volume":"180","author":"Bao","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020279","article-title":"Regulation of Bcl-2 family proteins in estrogen receptor-positive breast Cancer and their implications in endocrine therapy","volume":"14","author":"Kawiak","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0225","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000345467","article-title":"HER2\/neu, topoisomerase 2a, estrogen and progesterone receptors: discordance between primary breast cancer and metastatic axillary lymph node in expression and amplification characteristics","volume":"7","author":"Ataseven","year":"2012","journal-title":"Breast Care (Basel)"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0230","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12282-020-01142-8","article-title":"Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer","volume":"27","author":"Zhong","year":"2020","journal-title":"Breast Cancer (Tokyo, Japan)"},{"issue":"24","key":"10.1016\/j.bbcan.2026.189696_bb0235","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1158\/1078-0432.CCR-09-1450","article-title":"Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer","volume":"15","author":"Sparano","year":"2009","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189696_bb0240","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/532161","article-title":"Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer","volume":"2014","author":"Chen","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189696_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16244273","article-title":"Disrupted lipid metabolism, cytokine signaling, and dormancy: hallmarks of doxorubicin-resistant triple-negative breast Cancer models","volume":"16","author":"Vishnubalaji","year":"2024","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188898","article-title":"Exploring the role of CD151 in the tumor immune microenvironment: therapeutic and clinical perspectives","volume":"1878","author":"Malla","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189696_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100974","article-title":"GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells","volume":"69","author":"Zhu","year":"2023","journal-title":"Drug Resist. Updat."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0260","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41419-023-05972-0","article-title":"HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-\u03baB signaling pathway in breast cancer","volume":"14","author":"Liang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0265","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12967-025-06246-3","article-title":"Cancer-associated fibroblasts promote doxorubicin resistance in triple-negative breast cancer through enhancing ZFP64 histone lactylation to regulate ferroptosis","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0270","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10565-024-09980-4","article-title":"Molecular mechanism of ZC3H13 -mediated ferroptosis in doxorubicin resistance of triple negative breast cancer","volume":"41","author":"Huang","year":"2025","journal-title":"Cell Biol. Toxicol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0275","doi-asserted-by":"crossref","DOI":"10.1080\/15592294.2023.2217033","article-title":"METTL3-mediated m(6)A modification of lnc KCNQ1OT1 promotes doxorubicin resistance in breast cancer by regulating miR-103a-3p\/MDR1 axis","volume":"18","author":"Zhou","year":"2023","journal-title":"Epigenetics"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2023.130542","article-title":"METTL3\/IGF2BP3-regulated m6A modification of HYOU1 confers doxorubicin resistance in breast cancer","volume":"1868","author":"Zhou","year":"2024","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.bbcan.2026.189696_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102993","article-title":"M(6)a demethylase ALKBH5 regulates FOXO1 mRNA stability and chemoresistance in triple-negative breast cancer","volume":"69","author":"Liu","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.bbcan.2026.189696_bb0290","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9494910","article-title":"Exosome-mediated transfer of miR-3613-5p enhances doxorubicin resistance by suppression of PTEN expression in breast cancer cells","volume":"2022","author":"Luo","year":"2022","journal-title":"J. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0295","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10549-016-3829-5","article-title":"ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling","volume":"157","author":"Gelsomino","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189696_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16173025","article-title":"Estrogen-receptor loss and ESR1 mutation in estrogen-receptor-positive metastatic breast cancer and the effect on overall survival","volume":"16","author":"Westenend","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189696_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.592912","article-title":"Progress in the understanding of the mechanism of tamoxifen resistance in breast cancer","volume":"11","author":"Yao","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0310","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41419-023-06006-5","article-title":"circRNA-SFMBT2 orchestrates ER\u03b1 activation to drive tamoxifen resistance in breast cancer cells","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189696_bb0315","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1158\/0008-5472.CAN-22-2594","article-title":"A unique FOXA1-associated chromatin state dictates therapeutic resistance in lobular breast cancer","volume":"82","author":"Blawski","year":"2022","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.bbcan.2026.189696_bb0320","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.7150\/jca.59740","article-title":"HOXA5 confers tamoxifen resistance via the PI3K\/AKT signaling pathway in ER-positive breast cancer","volume":"12","author":"Kim","year":"2021","journal-title":"J. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0325","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.21873\/anticanres.15128","article-title":"HOXB5 confers tamoxifen resistance in breast cancer cells and promotes tumor aggression and progression","volume":"41","author":"Kim","year":"2021","journal-title":"Anticancer Res."},{"issue":"13","key":"10.1016\/j.bbcan.2026.189696_bb0330","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.7150\/thno.72599","article-title":"SETD1A-SOX2 axis is involved in tamoxifen resistance in estrogen receptor \u03b1-positive breast cancer cells","volume":"12","author":"Jin","year":"2022","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0335","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1021\/acs.chemrestox.1c00206","article-title":"ATF3 modulates the resistance of breast cancer cells to tamoxifen through an N(6)-methyladenosine-based epitranscriptomic mechanism","volume":"34","author":"Liu","year":"2021","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bbcan.2026.189696_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122684","article-title":"NF-\u03baB signaling in therapy resistance of breast cancer: mechanisms, approaches, and challenges","volume":"348","author":"Guo","year":"2024","journal-title":"Life Sci."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189696_bb0345","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.1074\/jbc.M116.763276","article-title":"Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6","volume":"292","author":"Yamaguchi","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2026.189696_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110723","article-title":"BRK confers tamoxifen-resistance in breast cancer via regulation of tyrosine phosphorylation of CDK1","volume":"108","author":"Mandapati","year":"2023","journal-title":"Cell. Signal."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189696_bb0355","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10555-022-10066-y","article-title":"The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options","volume":"41","author":"Wang","year":"2022","journal-title":"Cancer Metastasis Rev."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189696_bb0360","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000354253","article-title":"Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications","volume":"8","author":"Giuliano","year":"2013","journal-title":"Breast Care (Basel)"},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2026.189696_bb0365","article-title":"DNA repair pathways and cisplatin resistance: an intimate relationship","volume":"73","author":"Rocha","year":"2018","journal-title":"Clinics (Sao Paulo, Brazil)"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189696_bb0370","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s11596-023-2777-7","article-title":"TMED2 induces cisplatin resistance in breast cancer via targeting the KEAP1-Nrf2 pathway","volume":"43","author":"Liang","year":"2023","journal-title":"Curr. Med. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0375","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-021-01223-x","article-title":"HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189696_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216842","article-title":"SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG","volume":"590","author":"Li","year":"2024","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189696_bb0385","article-title":"HDAC2-mediated METTL3 delactylation promotes DNA damage repair and chemotherapy resistance in triple-negative breast cancer","volume":"12","author":"He","year":"2025","journal-title":"Adv. Sci. (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"10.1016\/j.bbcan.2026.189696_bb0390","article-title":"MYC\/TET3-regulated TMEM65 activates OXPHOS-SERPINB3 pathway to promote progression and cisplatin resistance in triple-negative breast cancer","author":"Zhang","year":"2025","journal-title":"Adv. Sci."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0395","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2174\/1566524022666220517102423","article-title":"Transcriptome profiling of cisplatin resistance in triple-negative breast cancer: new insight into the role of PI3k\/Akt pathway","volume":"23","author":"Memar","year":"2023","journal-title":"Curr. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0400","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00000421-198902000-00013","article-title":"Cisplatin and etoposide: an effective treatment for refractory breast carcinoma","volume":"12","author":"Cox","year":"1989","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0405","first-page":"838","article-title":"Endoplasmic reticulum stress confers 5-fluorouracil resistance in breast cancer cell via the GRP78\/OCT4\/lncRNA MIAT\/AKT pathway","volume":"10","author":"Yao","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26072964","article-title":"Synergistic effects of oxaliplatin, 5-fluorouracil, and novel synthetic uracil analog U-359 on breast cancer cell carcinogenesis","volume":"26","author":"D\u0142ugosz-Pokorska","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0415","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.3892\/ol.2017.5996","article-title":"Ell3 stimulates 5-FU resistance in a breast cancer cell line","volume":"13","author":"Kim","year":"2017","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0420","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neo.2018.01.001","article-title":"BAG3 overexpression and cytoprotective autophagy mediate apoptosis resistance in chemoresistant breast cancer cells","volume":"20","author":"Das","year":"2018","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0425","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11626-023-00832-9","article-title":"LINC00467 mediates the 5-fluorouracil resistance in breast cancer cells","volume":"60","author":"Li","year":"2024","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189696_bb0430","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1007\/s11033-022-07872-6","article-title":"ABCC6P1 pseudogene induces ABCC6 upregulation and multidrug resistance in breast cancer","volume":"49","author":"Hashemi","year":"2022","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0435","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/2211-5463.13324","article-title":"Tunneling nanotube formation promotes survival against 5-fluorouracil in MCF-7 breast cancer cells","volume":"12","author":"Kato","year":"2022","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bbcan.2026.189696_bb0440","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-031-30065-3_6","article-title":"Clinical use of PARP Inhibitors in BRCA mutant and non-BRCA mutant breast cancer","volume":"186","author":"Lynce","year":"2023","journal-title":"Cancer Treat. Res."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189696_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143642","article-title":"Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches","volume":"15","author":"Dilmac","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189696_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","article-title":"Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition","volume":"71","author":"Haynes","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0455","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","article-title":"Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors","volume":"3","author":"Jaspers","year":"2013","journal-title":"Cancer Discov."},{"issue":"7716","key":"10.1016\/j.bbcan.2026.189696_bb0460","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","article-title":"The shieldin complex mediates 53BP1-dependent DNA repair","volume":"560","author":"Noordermeer","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0465","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1038\/s41467-024-48637-y","article-title":"C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0470","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/0008-5472.CAN-23-1443","article-title":"Osteoclast cancer cell metabolic cross-talk confers PARP inhibitor resistance in bone metastatic breast cancer","volume":"84","author":"Fan","year":"2024","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189696_bb0475","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/s44321-024-00094-2","article-title":"FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer","volume":"16","author":"Tai","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189696_bb0480","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/978-3-031-70875-6_23","article-title":"CDK4\/6 inhibitor resistance in ER+ breast cancer","volume":"1464","author":"Migliaccio","year":"2025","journal-title":"Adv. Exp. Med. Biol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189696_bb0485","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000484167","article-title":"Mechanisms of resistance to CDK4\/6 Inhibitors in breast cancer and potential biomarkers of response","volume":"12","author":"Guarducci","year":"2017","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.bbcan.2026.189696_bb0490","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3389\/fonc.2019.00666","article-title":"Mechanisms of resistance to CDK4\/6 Inhibitors: potential implications and biomarkers for clinical practice","volume":"9","author":"McCartney","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189696_bb0495","article-title":"Mechanisms of CDK4\/6 inhibitor resistance in luminal breast Cancer","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189696_bb0500","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13050987","article-title":"Mechanisms of resistance to CDK4\/6 inhibitors and predictive biomarkers of response in HR+\/HER2-metastatic breast cancer\u2014a review of the literature","volume":"13","author":"Stanciu","year":"2023","journal-title":"Diagnostics"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0505","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.bbcan.2026.189696_bb0510","doi-asserted-by":"crossref","first-page":"13376","DOI":"10.3390\/ijms252413376","article-title":"The biological roles and clinical applications of the PI3K\/AKT pathway in targeted therapy resistance in HER2-positive breast cancer: a comprehensive review","volume":"25","author":"Zhong","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189696_bb0515","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0520","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","article-title":"Trastuzumab Deruxtecan resistance via loss of HER2 expression and binding","volume":"16","author":"Chen","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189696_bb0525","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1749-6632.2010.05782.x","article-title":"Primary trastuzumab resistance: new tricks for an old drug","volume":"1210","author":"Wilken","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0530","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00210-025-04480-6","article-title":"Paclitaxel-induced adverse effects: insights into multi-organ toxicities and molecular mechanisms","volume":"399","author":"Naeem","year":"2026","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189696_bb0535","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/onco.13697","article-title":"Weekly paclitaxel-induced neurotoxicity in breast cancer: outcomes and dose response","volume":"26","author":"Timmins","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189696_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113121","article-title":"Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems","volume":"324","author":"N.P. Staff","year":"2020","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189696_bb0545","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.clbc.2023.03.004","article-title":"Mild cryotherapy for prevention of paclitaxel-induced nail toxicity in breast cancer patients: a phase II single-arm clinical trial","volume":"23","author":"Mazzega-Fabbro","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bbcan.2026.189696_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.701424","article-title":"Case report: paclitaxel-induced pneumonitis in early breast cancer: a single institution experience and review","volume":"11","author":"Ardolino","year":"2021","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189696_bb0555","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/oxfordjournals.annonc.a059220","article-title":"Paclitaxel-induced neuropathy","volume":"6","author":"Postma","year":"1995","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189696_bb0560","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0565","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/CIRCRESAHA.119.314681","article-title":"Mitochondrial determinants of doxorubicin-induced cardiomyopathy","volume":"126","author":"Wallace","year":"2020","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0570","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0575","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1073\/pnas.1821022116","article-title":"Ferroptosis as a target for protection against cardiomyopathy","volume":"116","author":"Fang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0580","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10549-020-05887-w","article-title":"Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer trials group (CCTG) MA.21 experience","volume":"184","author":"Dent","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189696_bb0585","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/08820139.2021.1882486","article-title":"Interleukin-10 levels are associated with doxorubicin-related cardiotoxicity in breast cancer patients in a one-year follow-up study","volume":"51","author":"Alves","year":"2022","journal-title":"Immunol. Investig."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0590","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12012-022-09748-4","article-title":"microRNA miR-133a as a biomarker for doxorubicin-induced cardiotoxicity in women with breast cancer: a signaling pathway investigation","volume":"22","author":"Alves","year":"2022","journal-title":"Cardiovasc. Toxicol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0595","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(02)00003-8","article-title":"Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer -- a retrospective review of Chinese patients and comparison with an historic Western series","volume":"62","author":"Ma","year":"2002","journal-title":"Radiother. Oncol."},{"issue":"13","key":"10.1016\/j.bbcan.2026.189696_bb0600","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17132198","article-title":"Cardiotoxicity in elderly breast cancer patients","volume":"17","author":"Keramida","year":"2025","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105128","article-title":"Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care","volume":"10","author":"Dauccia","year":"2025","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0610","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3346\/jkms.2001.16.3.328","article-title":"5-fluorouracil-induced leukoencephalopathy in patients with breast cancer","volume":"16","author":"Choi","year":"2001","journal-title":"J. Korean Med. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0615","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/07357909909021422","article-title":"Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency","volume":"17","author":"Shehata","year":"1999","journal-title":"Cancer Investig."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0620","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cpt.2024.04.004","article-title":"Cardiotoxicity in platinum-based chemotherapy: mechanisms, manifestations, and management","volume":"3","author":"Rachma","year":"2025","journal-title":"Cancer Pathogen. Therapy"},{"key":"10.1016\/j.bbcan.2026.189696_bb0625","article-title":"A case report of cisplatin-induced cardiotoxicity: a side effect to monitor closely","volume":"3","author":"Mart\u00ednez-Mateo","year":"2017","journal-title":"J. Heart Health"},{"issue":"22","key":"10.1016\/j.bbcan.2026.189696_bb0630","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216545","article-title":"Molecular characteristics of cisplatin-induced ototoxicity and therapeutic interventions","volume":"24","author":"Tan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189696_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e04708","article-title":"The effect of some natural antioxidants against cisplatin-induced neurotoxicity in rats: behavioral testing","volume":"6","author":"Kandeil","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.bbcan.2026.189696_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113118","article-title":"Doxorubicin and cisplatin induced cognitive impairment: the possible mechanisms and interventions","volume":"324","author":"Ongnok","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbcan.2026.189696_bb0645","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3389\/fnins.2019.00907","article-title":"Pharmacological treatment of chemotherapy-induced neuropathic pain: PPAR\u03b3 agonists as a promising tool","volume":"13","author":"Quint\u00e3o","year":"2019","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0650","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.survophthal.2023.07.003","article-title":"Tamoxifen retinopathy: a comprehensive review","volume":"69","author":"Tenney","year":"2024","journal-title":"Surv. Ophthalmol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0655","article-title":"Unilateral tamoxifen-induced retinopathy as a consequence of breast cancer treatment-multimodal imaging value","volume":"13","author":"Szabelska","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189696_bb0660","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.survophthal.2023.02.003","article-title":"Tamoxifen retinopathy","volume":"68","author":"Bazvand","year":"2023","journal-title":"Surv. Ophthalmol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0665","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clbc.2016.07.003","article-title":"Cardiotoxicity of aromatase Inhibitors in breast cancer patients","volume":"17","author":"Foglietta","year":"2017","journal-title":"Clin. Breast Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0670","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10555-025-10283-1","article-title":"Hematological toxicity of parp inhibitors in solid tumors: a systematic review and safety meta-analysis","volume":"44","author":"Maiorano","year":"2025","journal-title":"Cancer Metastasis Rev."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0675","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database","volume":"12","author":"Shu","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbcan.2026.189696_bb0680","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1247270","volume":"13","author":"Cazzaniga","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0685","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.gendis.2017.07.007","article-title":"Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity","volume":"4","author":"Sadek","year":"2017","journal-title":"Genes & Diseases"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189696_bb0690","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000073","article-title":"Twenty years of anti-HER2 therapy-associated cardiotoxicity","volume":"1","author":"Pond\u00e9","year":"2016","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189696_bb0695","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s13258-025-01669-0","article-title":"Targeting the miR-325-3p\/GSTP1 axis overcomes paclitaxel resistance in triple-negative breast cancer by inducing ferroptosis","volume":"47","author":"Wang","year":"2025","journal-title":"Genes Genomics"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189696_bb0700","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41388-022-02559-5","article-title":"FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance","volume":"42","author":"Li","year":"2023","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.bbcan.2026.189696_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26146876","article-title":"PD-1\/PD-L1 Inhibitors and chemotherapy synergy: impact on drug resistance and PD-L1 expression in breast cancer-immune cell co-cultures","volume":"26","author":"\u00d6zen Ero\u011flu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189696_bb0710","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383456","article-title":"Targeting PD-1\/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges","volume":"15","author":"Javed","year":"2024","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189696_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2025.120059","article-title":"SYK overexpression enhances microtubule instability in an MDA-MB-231-derived paclitaxel-resistant cell line","volume":"1872","author":"Kuo","year":"2025","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0720","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005113","article-title":"Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-\u03b1 dependent signaling","volume":"10","author":"Aguirre-Ducler","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24356","article-title":"Transcriptomics analysis reveals distinct mechanism of breast cancer stem cells regulation in mammospheres from MCF-7 and T47D cells","volume":"10","author":"Hermawan","year":"2024","journal-title":"Heliyon"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189696_bb0730","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41401-024-01419-0","article-title":"STT3-mediated aberrant N-glycosylation of CD24 inhibits paclitaxel sensitivity in triple-negative breast cancer","volume":"46","author":"Wang","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbcan.2026.189696_bb0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103035","article-title":"DNAJC12 causes breast cancer chemotherapy resistance by repressing doxorubicin-induced ferroptosis and apoptosis via activation of AKT","volume":"70","author":"Shen","year":"2024","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0740","first-page":"517","article-title":"Research advances and new challenges in overcoming triple-negative breast cancer","volume":"4","author":"Zong","year":"2021","journal-title":"Cancer Drug Resist. (Alhambra, Calif.)"},{"key":"10.1016\/j.bbcan.2026.189696_bb0745","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.662232","article-title":"AKT inhibitors: new weapons in the fight against breast cancer?","volume":"12","author":"Martorana","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0750","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41698-024-00780-x","article-title":"HuR inhibition overcomes cFLIP-mediated doxorubicin resistance in triple-negative breast cancer","volume":"8","author":"Wei","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"25","key":"10.1016\/j.bbcan.2026.189696_bb0755","doi-asserted-by":"crossref","first-page":"23315","DOI":"10.1021\/acsnano.5c06302","article-title":"Mitochondria-targeted microneedles reverse doxorubicin resistance via apoptosis-ferroptosis synergy","volume":"19","author":"Hao","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbcan.2026.189696_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.126147","article-title":"CL4-modified exosomes deliver lncRNA DARS-AS1 siRNA to suppress triple-negative breast cancer progression and attenuate doxorubicin resistance by inhibiting autophagy","volume":"250","author":"Liu","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbcan.2026.189696_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122796","article-title":"Genetically engineered CD276-anchoring biomimetic nanovesicles target senescent escaped tumor cells to overcome chemoresistant and immunosuppressive breast cancer","volume":"313","author":"Liu","year":"2025","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0770","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1186\/s12967-024-05689-4","article-title":"Targeting CD276 for T cell-based immunotherapy of breast cancer","volume":"22","author":"Hagelstein","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189696_bb0775","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.freeradbiomed.2025.10.003","article-title":"Targeting the PRSS3-PAR2-ERK1\/2 axis inhibits malignancy and regulates chemosensitivity and resistance through ferroptosis in breast cancer","volume":"241","author":"Tian","year":"2025","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbcan.2026.189696_bb0780","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1134758","article-title":"Polyherbal formulation conjugated to gold nanoparticles induced ferroptosis in drug-resistant breast cancer stem cells through ferritin degradation","volume":"14","author":"Chittineedi","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0785","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41419-024-06814-3","article-title":"Targeting LINC00152 activates cAMP\/ca(2+)\/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer","volume":"15","author":"Saatci","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189696_bb0790","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-026-05171-6","article-title":"Targeting ZNF570 activates ferroptosis to reverse tamoxifen resistance in ER+breast cancer cells","author":"Ren","year":"2026","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189696_bb0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121827","article-title":"Targeting HMG-CoA synthase 2 suppresses tamoxifen-resistant breast cancer growth by augmenting mitochondrial oxidative stress-mediated cell death","volume":"328","author":"Hwang","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.bbcan.2026.189696_bb0800","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbrc.2022.02.083","article-title":"Knockdown of YAP\/TAZ sensitizes tamoxifen-resistant MCF7 breast cancer cells","volume":"601","author":"Kim","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0805","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s43440-021-00346-9","article-title":"Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer","volume":"74","author":"Attia","year":"2022","journal-title":"Pharmacol. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0810","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12964-024-01577-y","article-title":"CDK7 in breast cancer: mechanisms of action and therapeutic potential","volume":"22","author":"Gong","year":"2024","journal-title":"Cell Commun. Signal.: CCS"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189696_bb0815","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41416-024-02589-8","article-title":"Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer","volume":"130","author":"Song","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2026.189696_bb0820","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1126","article-title":"Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4\/6 inhibition: phase II SUMIT-BC study","volume":"42","author":"Pernas","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0825","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13058-019-1204-2","article-title":"Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51","volume":"21","author":"Lee","year":"2019","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0830","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3892\/or.2020.7898","article-title":"Enhancement of cisplatin sensitivity in human breast cancer MCF-7 cell line through BiP and 14-3-3\u03b6 co-knockdown","volume":"45","author":"Kashkoulinejad-Kouhi","year":"2021","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189696_bb0835","first-page":"1330","article-title":"Artemisinin induces selective and potent anticancer effects in drug resistant breast cancer cells by inducing cellular apoptosis and autophagy and G2\/M cell cycle arrest","volume":"25","author":"Guan","year":"2020","journal-title":"J. BUON"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0840","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1142\/S0192415X23500234","article-title":"Dihydroartemisinin affects STAT3\/DDA1 signaling pathway and reverses breast cancer resistance to cisplatin","volume":"51","author":"Zhang","year":"2023","journal-title":"Am. J. Chin. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0845","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13205-023-03582-3","article-title":"Pterostilbene-isothiocyanate reduces miR-21 level by impeding Dicer-mediated processing of pre-miR-21 in 5-fluorouracil and tamoxifen-resistant human breast cancer cell lines","volume":"13","author":"Kumar","year":"2023","journal-title":"3 Biotech"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189696_bb0850","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1111\/jcmm.14171","article-title":"Inhibition of circular RNA CDR1as increases chemosensitivity of 5-FU-resistant BC cells through up-regulating miR-7","volume":"23","author":"Yang","year":"2019","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0855","first-page":"66","article-title":"Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer","volume":"2","author":"Mehta","year":"2021","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0860","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41467-022-30568-1","article-title":"STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189696_bb0865","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/0008-5472.CAN-24-2531","article-title":"Harnessing STING signaling and natural killer cells overcomes PARP inhibitor resistance in homologous recombination-deficient breast cancer","volume":"85","author":"Pedretti","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189696_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110229","article-title":"Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells","volume":"91","author":"Guney Eskiler","year":"2022","journal-title":"Cell. Signal."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189696_bb0875","first-page":"1493","article-title":"Phase 1b clinical trial with Alpelisib plus Olaparib for patients with advanced triple-negative breast cancer","volume":"28","author":"Batalini","year":"2022","journal-title":"Clin. Canc. Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"28","key":"10.1016\/j.bbcan.2026.189696_bb0880","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0885","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0890","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA approval summary: Alpelisib plus Fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.bbcan.2026.189696_bb0895","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0900","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41467-025-67865-4","article-title":"CDK2 inhibitor BLU-222 synergizes with CDK4\/6 inhibitors in drug resistant breast cancers through p21\/p27 induction","volume":"17","author":"Luo","year":"2026","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189696_bb0905","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17121941","article-title":"Breaking cancer\u2019s momentum: CDK4\/6 Inhibitors and the promise of combination therapy","volume":"17","author":"Liu","year":"2025","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189696_bb0910","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189696_bb0915","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb0920","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189696_bb0925","first-page":"7281","article-title":"Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients","volume":"30","author":"Werida","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bbcan.2026.189696_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110539","article-title":"Polysaccharide from spore of Ganoderma lucidum ameliorates paclitaxel-induced intestinal barrier injury: apoptosis inhibition by reversing microtubule polymerization","volume":"130","author":"Li","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189696_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117066","article-title":"Nicotinamide riboside activates SIRT3 to prevent paclitaxel-induced peripheral neuropathy","volume":"491","author":"Sun","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189696_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.103024","article-title":"Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy","volume":"70","author":"Huang","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.bbcan.2026.189696_bb0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111308","article-title":"Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation","volume":"137","author":"Wu","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189696_bb0950","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1177\/10781552221118530","article-title":"Protective effects of Panax ginseng against doxorubicin-induced cardiac toxicity in patients with non-metastatic breast cancer: a randomized, double-blind, placebo-controlled clinical trial","volume":"29","author":"Hamidian","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189696_bb0955","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clbc.2022.01.008","article-title":"The cardioprotective effect of vitamin D in breast cancer patients receiving adjuvant doxorubicin based chemotherapy","volume":"22","author":"El-Bassiouny","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bbcan.2026.189696_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.152311","article-title":"Investigating the role of ketogenic diet and high-dose vitamin C in modulating doxorubicin toxicity in a murine breast cancer model","volume":"777","author":"Al-Jada","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189696_bb0965","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/10781552231171114","article-title":"A prospective study to evaluate the efficacy and safety of vitamin E and levocarnitine prophylaxis against doxorubicin-induced cardiotoxicity in adult breast cancer patients","volume":"30","author":"Moustafa","year":"2024","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.bbcan.2026.189696_bb0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114087","article-title":"Kaempferol attenuates doxorubicin-induced renal tubular injury by inhibiting ROS\/ASK1-mediated activation of the MAPK signaling pathway","volume":"157","author":"Wu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189696_bb0975","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lfs.2015.11.018","article-title":"Baicalein alleviates doxorubicin-induced cardiotoxicity via suppression of myocardial oxidative stress and apoptosis in mice","volume":"144","author":"Sahu","year":"2016","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189696_bb0980","first-page":"31","article-title":"The effects of baicalein alone and in combination with losartan on DOX-induced nephrotoxicity in rats","volume":"36","author":"Al-Oanzi","year":"2023","journal-title":"Pak. J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189696_bb0985","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/10286020.2025.2481273","article-title":"Baicalein: unveiling the multifaceted marvel of hepatoprotection and beyond","volume":"27","author":"Dogra","year":"2025","journal-title":"J. Asian Nat. Prod. Res."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189696_bb0990","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5483\/BMBRep.2020.53.5.041","article-title":"Sulfasalazine attenuates tamoxifen-induced toxicity in human retinal pigment epithelial cells","volume":"53","author":"Hwang","year":"2020","journal-title":"BMB Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189696_bb0995","doi-asserted-by":"crossref","DOI":"10.3390\/medicina62040787","article-title":"Protective role of adenosine triphosphate against tamoxifen-induced retinal toxicity in a rat model","volume":"62","author":"Karatas","year":"2026","journal-title":"Medicina"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189696_bb1000","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s11255-020-02485-z","article-title":"Vinpocetine reduces cisplatin-induced acute kidney injury through inhibition of NF-\u03baB pathway and activation of Nrf2\/ARE pathway in rats","volume":"52","author":"Song","year":"2020","journal-title":"Int. Urol. Nephrol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189696_bb1005","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202504778R","article-title":"Germacrone alleviates cisplatin-induced nephrotoxicity by activating PI3K\/Akt signaling, inhibiting Ras\/MAPK signaling, and regulating macrophage polarization","volume":"40","author":"Zheng","year":"2026","journal-title":"FASEB J."},{"key":"10.1016\/j.bbcan.2026.189696_bb1010","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.867867","article-title":"An olive oil mill wastewater extract improves chemotherapeutic activity against breast cancer cells while protecting from cardiotoxicity","volume":"9","author":"Benedetto","year":"2022","journal-title":"Front. Cardiovasc. Med."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X2600168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X2600168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:25:05Z","timestamp":1789518305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X2600168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":202,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0304419X2600168X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189696","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapy-induced resistance and toxicity in breast cancer: Sensitization and mitigation strategies","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189696"}}